David Segal

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations

Medicine, Oncology, Pharmacology +11

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

Mary Ann Anderson, Jing Deng, John F. Seymour et al. · Blood · 2016 · 329 citations · Full text

Life Sciences, Cell Biology, Oncology +13

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

Delphine Mérino, James R. Whittle, François Vaillant et al. · Science Translational Medicine · 2017 · 192 citations

Medicine, Oncology, Pharmacology +14

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

Erinna F. Lee, Tiffany J. Harris, Sharon Tran et al. · Cell Death and Disease · 2019 · 186 citations · Full text

Medicine, Oncology, Pharmacology +17

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

Donia M. Moujalled, Giovanna Pomilio, Corina Ghiurau et al. · Leukemia · 2018 · 174 citations · Full text

Medicine, Oncology, Pharmacology +17